Skip to main content
OpenTrials
Completed

NCT Number: NCT01464983

Placebo and Active Controlled, Double Dummy Study to Compare Efficacy of Aspirin and Ibuprofen in Treatment of Episodic Tension-type Headache

The purpose of this study is to determine the efficacy and tolerability of 500 mg and 1000 mg Aspirin® (study medication) by comparing it to placebo (the control group without active substance) or 200 mg or 400 mg Ibuprofen (study medication) in treating the symptoms of episodic tension-type headache. The study is designed to develop a treatment method against episodic tension-type headache which will have more advantages for patients than the methods that are currently available.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Reading, Berkshire, United Kingdom

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Ambulatory male or female, 18 to 65 years of age
  • Normal blood pressure
  • Patients suffering from episodic tension-type headache
  • Headache lasting from 30 minutes to 7 days
  • Headache had at least two of the following characteristics:

Bilateral location. Pressing/tightening (non-pulsating). Mild or moderate intensity. Not aggravated by routine physical activity such as walking or climbing stairs.

  • Both of the following: No nausea or vomiting. No more than one of photophobia or phonophobia.

Exclusion criteria

  • Other headaches, including migraine, that required medical treatment
  • Hypersensitivity to acetylsalicylic acid, salicylates, ibuprofen or other non-steroidal anti-inflammatory drugs (NSAIDs)
  • Serious physical illness especially uncontrolled disorders of kidney, liver, lung, heart or brain function, neurological disorders or severe chronic or terminal disease
  • Mental illness, including depression
  • Needed or were using or likely to need or use any of the prohibited concomitant medications: antidepressants, oxicams
  • Pregnant or lactating women, or sexually active women of child-bearing potential unless using effective contraception
  • Participating in any other clinical study or had done within the previous 4 weeks
  • Had been previously enrolled in this study

Treatment and study plan

Acetylsalicylic acid (Aspirin, BAYE4465)

Drug

Acetylsalicylic acid 500 mg orally, single dose, 1 tablet; in addition, 1 Placebo tablet of Acetylsalicylic acid, and 2 Placebo tablets of Ibuprofen

Ibuprofen

Drug

Ibuprofen 200 mg orally, single dose, 1 tablet; in addition, 1 Placebo tablet of Ibuprofen, and 2 Placebo tablets of Acetylsalicylic Acid

Placebo

Drug

2 Placebo tablets of Acetylsalicylic Acid, and 2 Placebo tablets of Ibuprofen, orally, single dose

Primary outcomes

  1. Percentage of subjects with total or meaningful headache relief at 2 hours after intake of study medication

    Time frame: 2 hours post dose

Secondary outcomes

  1. Headache pain relief measured serially on a categorical scale

    Time frame: Until 4 hours post dose

  2. Measuring the functional ability on conducting everydays activity on a 4 point categorical scale

    Time frame: 2 and 24 hours post dose

  3. Global assessment of pain therapy

    Time frame: 24 hours post dose

  4. Safety - assessment of adverse events

    Time frame: Up to 10 weeks after screening

Sponsors and collaborators

Lead sponsor

Bayer

Industry

Registry information

Official study title

A Multicentre Randomised Parallel-groups Double-blind Double-dummy Single-dose Study to Compare Acetylsalicylic Acid 500 mg and 1,000 mg With Ibuprofen 200 mg and 400 mg and Placebo for Tolerability and Efficacy in the Treatment of Episodic Tension-type Headache

Important dates

Study start
2004
Study completion
2004
First posted
Nov 4, 2011
Registry last updated
Dec 25, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.